Jonathan Uecker, MD
Psychiatry · New Brighton, MNNPI 1659334092
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,613 of the $7,963 with a category attached, or 95.6%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 96.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $4,212 and has fallen 99.3% since, to $28 in 2025. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $248.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
- Sunovion Pharmaceuticals Inc.$80
- Tempus AI, Inc$58
- Alkermes, Inc.$50
- Vanda Pharmaceuticals Inc.$41
- Teva Pharmaceuticals USA, Inc.$29
- plus $65 from 4 others
What the payments were for
- Speaking & faculty fees$7,61396%
- Food & beverage$3504%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $7,640 |
| Sunovion Pharmaceuticals Inc. | 7 | $80 |
| Tempus AI, Inc | 2 | $58 |
| Alkermes, Inc. | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| AbbVie(2 entities) | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Corium, LLC | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$7,613
How this compares
$7,963 in reported general payments places this provider in the 95th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 39 | $271,131 |
| AuvelityDextromethorphan Hbr/Bupropion | 105 | $119,796 |
| IngrezzaValbenazine Tosylate | 13 | $109,747 |
| Abilify MaintenaAripiprazole | 22 | $65,409 |
| VraylarCariprazine Hcl | 34 | $59,573 |
| RexultiBrexpiprazole | 30 | $49,161 |
| Invega SustennaPaliperidone Palmitate | 18 | $45,331 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $41,597 |
| FetzimaLevomilnacipran Hcl | 48 | $28,862 |
| TrintellixVortioxetine Hydrobromide | 22 | $28,721 |
| Aripiprazole | 224 | $26,246 |
| Clozapine | 354 | $20,635 |
| Quetiapine Fumarate | 510 | $12,813 |
| BelsomraSuvorexant | 23 | $11,197 |
| Olanzapine | 272 | $11,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $29 | $271,13139 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $12 | $109,74713 claims |
| AbbVieVraylar, Fetzima | $26 | $88,43582 claims |
| Alkermes, Inc.Lybalvi | $50 | $41,59727 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $14 | $38,53748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in New Brighton
- Sujit VarmaEdina$581K
- Michael FarnsworthMankato$548K
- Danielle Magness-WellmannMankato$232K
- Craig VineSt Paul$136K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
- John SimonMinneapolis$32K
- Ziad NahasMinneapolis$32K
- Sophia VinogradovMinneapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.